← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV25행 · 1개 프로그램
OverviewMoAPK/PDToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyLimited DatastalePhase 2
rabbit (antithymocyte globulin, antithymocyte globulin (rabbit))
Genzyme, a Sanofi Company·Acute Lymphoblastic Leukemia
203 trials
Overview
Program
antithymocyte globulin (rabbit)
Overview
Company
Genzyme, a Sanofi Company
Overview
Modality
ANTIBODY
Overview
Target
Acute Lymphoblastic Leukemia
Overview
Indication
Acute Lymphoblastic Leukemia; Acute Myelocytic Leukemia
Overview
Phase
PHASE_2
Overview
Status
DISCONTINUED
Overview
Content status
Limited Data
Overview
Data Confidence
Data Confidence · Low
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
MoA
Mechanism
targeting chimeric antigen receptor
MoA
Biomarker
biomarker discovery, and personalized oncology applications, preserving the genomic landscape, intratumor het
PK/PD
Species
Rabbit, Human
PK/PD
Animal (cat.)
Human, In vitro
PK/PD
Experiment
pharmacokinetic
Toxicology
Species
Rabbit, Human
Toxicology
Animal (cat.)
Human, In vitro
Toxicology
Major finding
hepatotoxicity
Clinical
Safety signal
hepatotoxicity
Clinical
Reported PFS
0.31
Clinical
Result source
ClinicalTrials.gov NCT01131169
Clinical
Program phase
PHASE_2
Clinical
Trial activity
No active/completed counts
Clinical
Trial ref
NCT01131169